Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors

Oncology Reports

Volumn 15, Issue 4, 2006, Pages 773-778

  Sui, Li ^a   Dong, Youyi ^a   Watanabe, Yasuo ^a   Yamaguchi, Fuminori ^a   Sugimoto, Katsuyoshi ^a   Tokuda, Masaaki ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Ovarian tumor; PTEN; Survivin

Indexed keywords

BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR PROTEIN;

ARTICLE; BIOSYNTHESIS; CHEMISTRY; EPITHELIUM CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL;

EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SURVIVAL ANALYSIS;

EID: 33746425410     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.4.773     Document Type: Article

References (43)

1. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997. (Pubitemid 27148818)
2. Steck PA, Pershouse MA, Jasser SA, et al: Identification of a candidate tumor suppressor gene, MMAC1 at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997. (Pubitemid 27147102)
3. Tamura M, Gu J, Takino T and Yamada KM: Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130cas. Cancer Res 59: 4342-4349, 1999.
4. Sakudra A, Hamada H, Fukushige S, et al: Adenovirus mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer. Int J Oncol 15: 1069-1074, 1999.
5. Cheney IW, Neuteboom ST, Vaillancourt MT, Ramachandra M and Bookstein R: Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27 KIP1 into cyclin E/CDK2 complexes. Cancer Res 59: 2318-2323, 1999. (Pubitemid 29242275)
6. Li DM and Sun H: PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95: 15406-15411, 1998.
7. Weng LP, Smith WM, Dahia PL, Ziebold U, Gil E, Lees JA and Eng C: PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 59: 5808-5814, 1999.
8. Stambolic V, Suzuki A, de la Pompa JL, et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39, 1998. (Pubitemid 28458022)
9. Depowski PL, Rosenthal SI and Ross JS: Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14: 672-676, 2001. (Pubitemid 32667211)
10. Sano T, Lin H, Chen X, et al : Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59: 1820-1824, 1999. (Pubitemid 29186149)
11. Lee HS, Lee HK, Kim HS, Yang HK and Kim WH: Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 200: 39-46, 2003. (Pubitemid 36592634)
12. Tachibana M, Shibakita M, Ohno S, et al: Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer 94: 1955-1960, 2002. (Pubitemid 34270048)
13. Terakawa N, Kanamori Y and Yoshida S: Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 10: 203-208, 2003. (Pubitemid 36758649)
14. Risinger JI, Hayes AK, Berchuck A and Barett JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57: 4736-4738, 1997. (Pubitemid 27468978)
15. Tashiro H, Blazes MS, Wu R, et al: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935-3940, 1997. (Pubitemid 27427679)
16. Cardone MH, Roy N, Stennicke HR, et al: Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321, 1998. (Pubitemid 28524494)
17. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997. (Pubitemid 27353455)
18. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998. (Pubitemid 28551107)
19. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K and Tokuda M: Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 21: 315-320, 2002.
20. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M and Altieri DC: Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351: 882-883, 1998. (Pubitemid 28121185)
21. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074, 1998. (Pubitemid 28521163)
22. Sarela AI, Macadam RC, Farmery SM, Markham AF and Guillou PJ: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46: 645-650, 2000. (Pubitemid 30305781)
23. Monzo M, Rosell R and Felip E, et al: A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17: 2100-2104, 1999. (Pubitemid 29318841)
24. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M and Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134, 2000. (Pubitemid 30064984)
25. Kato J, Kuwabara Y and Mitani M, et al: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer (Pred Oncol) 95: 92-95, 2001. (Pubitemid 32187079)
26. Kim S, Kang J, Qiao J, Thomas RP, Evers BM and Chung DH: Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J Pediatr Surg 39: 516-521, 2004. (Pubitemid 38500368)
27. Carter BZ, Milella M, Altieri DC and Andreeff M: Cytokine-regulated expression of survivin in myeloid leukemia. Blood 197: 2784-2790, 2001.
28. Papapetropoulos A, Fulton D, Mahboubi K, et al: Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275: 9102-9105, 2000. (Pubitemid 30185122)
29. Ohashi H, Takagi H, Oh H, et al: Phosphatidylinositol 3-kinase/Akt regulates angiotensin II-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity. Circ Res 94: 785-793, 2004. (Pubitemid 38451740)
30. Fornaro M, Plescia J, Chheang S, et al: Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem 278: 50402-50411, 2003. (Pubitemid 37548884)
31. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER and Eng C: Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158: 2097-2106, 2001. (Pubitemid 32545195)
32. Schondorf T, Gohring UJ, Roth G, et al: Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients. Eur J Clin Invest 33: 256-260, 2003. (Pubitemid 36411545)
33. An HJ, Lee YH, Cho NH, Shim JY, Kim JY, Lee C and Kim SJ: Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology 41: 437-445, 2002. (Pubitemid 35335004)
34. Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L and Parsons R: Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 33: 405-409, 2002. (Pubitemid 34627590)
35. Halvorsen OJ, Haukaas SA and Akslen LA: Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 9: 1474-1479, 2003. (Pubitemid 36418404)
36. Soria JC, Lee HY, Lee JI, et al: Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8: 1178-1184, 2002. (Pubitemid 34517656)
37. Leslie NR and Downes CP: PTEN: the down side of PI 3-kinase signalling. Cell Signal 14: 285-295, 2002. (Pubitemid 34164684)
38. Sulis ML and Parsons R: PTEN: from pathology to biology. Trends Cell Biol 13: 478-483, 2003. (Pubitemid 37289398)
39. Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262, 2003. (Pubitemid 37329790)
40. Sansal I and Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963, 2004. (Pubitemid 41079915)
41. Parsons R: Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 15: 171-176, 2004.
42. Obata K, Morland SJ, Watson RH, Hitchcock A, Thomas EJ, Chenevix-Trench G and Campbell IG: Frequent PTEN/MMAC mutations in endometrioid, but not serous or mucinous epithelial ovarian tumors. Cancer Res 58: 2095-2097, 1998. (Pubitemid 28232892)
43. Lachyankar MB, Sultana N, Schonhoff CM, et al: A role for nuclear PTEN in neuronal differentiation. J Neurosci 20: 1404-1413, 2000. (Pubitemid 30220420)